… into AR-V expression in prostate cancers and their implications in contemporary prostate
cancer clinical care, as well as current efforts in therapeutic targeting of AR-Vs aiming to …

… targeting therapies but may retain sensitivity to chemotherapy. Here, we discuss the clinical
implications … whether such variants are passengers or drivers of aggressive clinical behavior. …

… and therapeutic targets in prostate cancer. Laboratory investigations reveal both challenges
… opportunities in targeting AR-Vs to overcome resistance to current AR-directed therapies. …

… to overcome AR splice variant-driven disease. Galeterone (formerly TOK-001) is one potential
AR-V7-targeting drug that is the most advanced in its clinical development. In addition to …

… Given the important clinical implication of AR-Vs, this short … Therapeutic targeting of the AR
axis may result in active transcription … with AR-V-specific activities, in AR variant-driven CRPC. …

… of AR-Vs as therapeutic targets in CRPC. … clinical trials for Astellas, Pfizer, Janssen, Sanofi,
ESSA, and Arno that have an interest in targeting the androgen receptor in prostate cancer; …

… cancer drivers, and consequences of therapeutic pressures. With regard to the fundamental
importance of the androgen receptor (AR… role in castration-resistant prostate cancer (CRPC). …

… The central question regarding the clinical significance of AR-V7 splice variant expression
in CRPC is whether it is simply a marker of enhanced AR transcription characteristic of …

… cause of cancer death among men. Although therapies targeting the androgen receptor (AR) …
is universal and remains a major therapeutic challenge. Nonetheless, signaling via AR is …

… on inhibiting the androgen receptor (AR) through targeting of its C-… to androgen deprivation
and anti-androgen therapies, … unlikely that this variant is of major clinical significance in PCa. …